The Filings Report

ZOETIS INC.

ZTSNYSECIK 1555280Healthcare / Drug Manufacturersfiscal year ends December58 quarters since 2012

Revenue, Q2 FY2026
$2.5B
−0.2% on Q2 FY2025
Net income
$691M
−4.8% on Q2 FY2025
Free cash flow
$538M
+17.2% on Q2 FY2025
Diluted EPS
$1.65
+1.2% on Q2 FY2025
Revenue, TTM
$9.5B
trailing four quarters
Net margin, TTM
27.5%
net income $2.6B
Free cash flow, TTM
$2.3B
$2.8B less $524M capex
Cash and equivalents
$1.5B
long-term debt $9.0B, Jun 30, 2026
Shares, 12-month change
−6.8%
413M shares, Jun 30, 2026, split-adjusted
Buybacks, TTM
$3.6B
11.1% of market value
Dividends, TTM
—
no yield
Market value
$32.9B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 6, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, ZOETIS INC. reported revenue of $2.5B, −0.2% on Q2 FY2025, and net income of $691M (−4.8%). Free cash flow, operating cash flow less capital expenditures, was $538M ($655M less $117M). Diluted earnings per share were $1.65.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 6, 2026.

Revenue and net incomeRevenueNet income
$0$1B$2B$3BQ3'22, Revenue: $2.0BQ3'22, Net income: $529MQ3'22Q4'22, Revenue: $2.0BQ4'22, Net income: $461MQ4'22Q1'23, Revenue: $2.0BQ1'23, Net income: $552MQ1'23Q2'23, Revenue: $2.2BQ2'23, Net income: $671MQ2'23Q3'23, Revenue: $2.2BQ3'23, Net income: $596MQ3'23Q4'23, Revenue: $2.2BQ4'23, Net income: $525MQ4'23Q1'24, Revenue: $2.2BQ1'24, Net income: $599MQ1'24Q2'24, Revenue: $2.4BQ2'24, Net income: $624MQ2'24Q3'24, Revenue: $2.4BQ3'24, Net income: $682MQ3'24Q4'24, Revenue: $2.3BQ4'24, Net income: $581MQ4'24Q1'25, Revenue: $2.2BQ1'25, Net income: $602MQ1'25Q2'25, Revenue: $2.5BQ2'25, Net income: $726MQ2'25Q3'25, Revenue: $2.4BQ3'25, Net income: $721MQ3'25Q4'25, Revenue: $2.4BQ4'25, Net income: $603MQ4'25Q1'26, Revenue: $2.3BQ1'26, Net income: $601MQ1'26Q2'26, Revenue: $2.5BQ2'26, Net income: $691MQ2'26$0$1B$2B$3BQ3'22, Revenue: $2.0BQ3'22, Net income: $529MQ4'22, Revenue: $2.0BQ4'22, Net income: $461MQ4'22Q1'23, Revenue: $2.0BQ1'23, Net income: $552MQ2'23, Revenue: $2.2BQ2'23, Net income: $671MQ2'23Q3'23, Revenue: $2.2BQ3'23, Net income: $596MQ4'23, Revenue: $2.2BQ4'23, Net income: $525MQ4'23Q1'24, Revenue: $2.2BQ1'24, Net income: $599MQ2'24, Revenue: $2.4BQ2'24, Net income: $624MQ2'24Q3'24, Revenue: $2.4BQ3'24, Net income: $682MQ4'24, Revenue: $2.3BQ4'24, Net income: $581MQ4'24Q1'25, Revenue: $2.2BQ1'25, Net income: $602MQ2'25, Revenue: $2.5BQ2'25, Net income: $726MQ2'25Q3'25, Revenue: $2.4BQ3'25, Net income: $721MQ4'25, Revenue: $2.4BQ4'25, Net income: $603MQ4'25Q1'26, Revenue: $2.3BQ1'26, Net income: $601MQ2'26, Revenue: $2.5BQ2'26, Net income: $691MQ2'26

Net income losses drawn in red.

Free cash flow
$0$200M$400M$600M$800MQ3'22, Free cash flow: $372MQ3'22Q4'22, Free cash flow: $570MQ4'22Q1'23, Free cash flow: $326MQ1'23Q2'23, Free cash flow: $17MQ2'23Q3'23, Free cash flow: $579MQ3'23Q4'23, Free cash flow: $699MQ4'23Q1'24, Free cash flow: $455MQ1'24Q2'24, Free cash flow: $370MQ2'24Q3'24, Free cash flow: $784MQ3'24Q4'24, Free cash flow: $689MQ4'24Q1'25, Free cash flow: $337MQ1'25Q2'25, Free cash flow: $459MQ2'25Q3'25, Free cash flow: $755MQ3'25Q4'25, Free cash flow: $732MQ4'25Q1'26, Free cash flow: $291MQ1'26Q2'26, Free cash flow: $538MQ2'26$0$200M$400M$600M$800MQ3'22, Free cash flow: $372MQ4'22, Free cash flow: $570MQ4'22Q1'23, Free cash flow: $326MQ2'23, Free cash flow: $17MQ2'23Q3'23, Free cash flow: $579MQ4'23, Free cash flow: $699MQ4'23Q1'24, Free cash flow: $455MQ2'24, Free cash flow: $370MQ2'24Q3'24, Free cash flow: $784MQ4'24, Free cash flow: $689MQ4'24Q1'25, Free cash flow: $337MQ2'25, Free cash flow: $459MQ2'25Q3'25, Free cash flow: $755MQ4'25, Free cash flow: $732MQ4'25Q1'26, Free cash flow: $291MQ2'26, Free cash flow: $538MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$3B$5B$8B$10BQ3'22, Cash and equivalents: $2.5BQ3'22, Long-term debt: $5.2BQ3'22Q4'22, Cash and equivalents: $3.6BQ4'22, Long-term debt: $6.6BQ4'22Q1'23, Cash and equivalents: $2.1BQ1'23, Long-term debt: $6.6BQ1'23Q2'23, Cash and equivalents: $1.7BQ2'23, Long-term debt: $6.6BQ2'23Q3'23, Cash and equivalents: $1.8BQ3'23, Long-term debt: $6.6BQ3'23Q4'23, Cash and equivalents: $2.0BQ4'23, Long-term debt: $6.6BQ4'23Q1'24, Cash and equivalents: $2.0BQ1'24, Long-term debt: $6.6BQ1'24Q2'24, Cash and equivalents: $1.6BQ2'24, Long-term debt: $6.6BQ2'24Q3'24, Cash and equivalents: $1.7BQ3'24, Long-term debt: $6.6BQ3'24Q4'24, Cash and equivalents: $2.0BQ4'24, Long-term debt: $5.2BQ4'24Q1'25, Cash and equivalents: $1.7BQ1'25, Long-term debt: $5.2BQ1'25Q2'25, Cash and equivalents: $1.4BQ2'25, Long-term debt: $5.2BQ2'25Q3'25, Cash and equivalents: $2.1BQ3'25, Long-term debt: $7.1BQ3'25Q4'25, Cash and equivalents: $2.5BQ4'25, Long-term debt: $9.0BQ4'25Q1'26, Cash and equivalents: $1.9BQ1'26, Long-term debt: $9.0BQ1'26Q2'26, Cash and equivalents: $1.5BQ2'26, Long-term debt: $9.0BQ2'26$0$3B$5B$8B$10BQ3'22, Cash and equivalents: $2.5BQ3'22, Long-term debt: $5.2BQ4'22, Cash and equivalents: $3.6BQ4'22, Long-term debt: $6.6BQ4'22Q1'23, Cash and equivalents: $2.1BQ1'23, Long-term debt: $6.6BQ2'23, Cash and equivalents: $1.7BQ2'23, Long-term debt: $6.6BQ2'23Q3'23, Cash and equivalents: $1.8BQ3'23, Long-term debt: $6.6BQ4'23, Cash and equivalents: $2.0BQ4'23, Long-term debt: $6.6BQ4'23Q1'24, Cash and equivalents: $2.0BQ1'24, Long-term debt: $6.6BQ2'24, Cash and equivalents: $1.6BQ2'24, Long-term debt: $6.6BQ2'24Q3'24, Cash and equivalents: $1.7BQ3'24, Long-term debt: $6.6BQ4'24, Cash and equivalents: $2.0BQ4'24, Long-term debt: $5.2BQ4'24Q1'25, Cash and equivalents: $1.7BQ1'25, Long-term debt: $5.2BQ2'25, Cash and equivalents: $1.4BQ2'25, Long-term debt: $5.2BQ2'25Q3'25, Cash and equivalents: $2.1BQ3'25, Long-term debt: $7.1BQ4'25, Cash and equivalents: $2.5BQ4'25, Long-term debt: $9.0BQ4'25Q1'26, Cash and equivalents: $1.9BQ1'26, Long-term debt: $9.0BQ2'26, Cash and equivalents: $1.5BQ2'26, Long-term debt: $9.0BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 6, 2026.

ZOETIS INC. income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025Q3 FY2024ended Sep 30, 2024filed Nov 4, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue2,4682,2622,3872,4002,4742,1982,3172,388−0.2%
Cost of revenue673641712683664618707701+1.4%
Gross profit—————————
Research and development—————————
Selling, general and administrative592588619579614574625565−3.6%
Operating income—————————
Other income (expense)520913(2)152016+350.0%
Pretax income866758761887912773732874−5.0%
Income tax175157158166186171151182−5.9%
Net income691601603721726602581682−4.8%
Diluted EPS ($)1.651.42—1.631.631.34—1.50+1.2%
Diluted shares (millions)418422—443446448—454—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 6, 2026.

ZOETIS INC. balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025Q3 FY2024ended Sep 30, 2024filed Nov 4, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents1,4761,9412,4502,0841,4351,7211,9871,714+2.9%
Short-term investments200—0——————
Total current assets6,3566,4746,7736,5835,9235,8775,9866,282+7.3%
Total assets15,07715,15415,49015,15914,47914,09814,23714,357+4.1%
Total current liabilities2,0612,0532,1731,8073,3663,3853,4121,702−38.8%
Long-term debt9,0489,0459,0427,0695,2315,2275,2206,574+73.0%
Total liabilities11,92911,92112,0759,7619,5029,4439,4679,123+25.5%
Stockholders’ equity3,1483,2333,4155,3984,9774,6554,7705,234−36.7%
Shares outstanding (millions)413419422441443445448451—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 6, 2026.

ZOETIS INC. cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025Q3 FY2024ended Sep 30, 2024filed Nov 4, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow655401893891605515905951+8.3%
Capital expenditures117110161136146178216167−19.9%
Free cash flow (CFO − capex)538291732755459337689784+17.2%
Depreciation and amortization119119121124124119123121−4.0%
Share repurchases5846062,060394338443553433+72.8%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 12, 2026.

Income statement

ZOETIS INC. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 13, 2024FY2022ended Dec 31, 2022filed Feb 14, 2023FY2021ended Dec 31, 2021filed Feb 15, 2022FY2020ended Dec 31, 2020filed Feb 16, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 14, 2019FY2017ended Dec 31, 2017filed Feb 15, 2018FY2016ended Dec 31, 2016filed Feb 16, 2017FY2015ended Dec 31, 2015filed Feb 24, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Mar 26, 2014FY2012ended Dec 31, 2012filed May 15, 2013FY2011ended Dec 31, 2011filed May 15, 2013
Revenue9,4679,2568,5448,0807,7766,6756,2605,8255,3074,8884,7654,7854,5614,3364,233
Cost of revenue2,6662,7192,5612,4542,3032,0571,9921,9111,7751,6661,7381,7171,6691,5631,652
Gross profit———————————————
Research and development———————————————
Selling, general and administrative2,3782,3182,1512,0092,0011,7261,6381,4841,3341,3641,5321,6431,6131,4701,453
Operating income———————————————
Other income (expense)3619159(40)(48)(17)5783(6)2(81)(7)946(48)
Pretax income3,3603,1332,9362,6562,4881,9961,8011,6901,5251,228545820690710394
Income tax687637596545454360301266663409206233187274146
Net income2,6732,4862,3442,1142,0371,6381,5001,428864821339583504436245
Diluted EPS ($)6.025.475.074.494.273.423.112.931.751.650.681.161.010.870.49
Diluted shares (millions)444455462470477479482487493498502502500500500

Balance sheet

ZOETIS INC. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 13, 2024FY2022ended Dec 31, 2022filed Feb 14, 2023FY2021ended Dec 31, 2021filed Feb 15, 2022FY2020ended Dec 31, 2020filed Feb 16, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 14, 2019FY2017ended Dec 31, 2017filed Feb 15, 2018FY2016ended Dec 31, 2016filed Feb 16, 2017FY2015ended Dec 31, 2015filed Feb 24, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Mar 26, 2014FY2012ended Dec 31, 2012filed May 15, 2013FY2011ended Dec 31, 2011filed May 15, 2013
Cash and equivalents2,4501,9872,0413,5813,4853,6041,9341,6021,5647271,15488261031779
Short-term investments0—————0990——————
Total current assets6,7735,9866,3437,5066,9306,6114,7484,3994,2173,3903,8303,4653,3572,864—
Total assets15,49014,23714,28614,92513,90013,60911,54510,7778,5867,6497,9136,5886,5586,262—
Total current liabilities2,1733,4121,8893,1671,7972,1701,8061,2231,0941,1171,7811,0861,4151,123—
Long-term debt9,0425,2206,5646,5526,5926,5955,9476,4434,9534,4684,4633,6243,6420—
Total liabilities12,0759,4679,29510,5229,3569,8368,8378,5926,8006,1506,8225,2515,5962,221—
Stockholders’ equity3,4154,7704,9974,4054,5433,7692,7082,1851,7701,4871,0681,3119404,026—
Shares outstanding (millions)422448458463472475475479485492497501501——

Cash flow statement

ZOETIS INC. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 13, 2024FY2022ended Dec 31, 2022filed Feb 14, 2023FY2021ended Dec 31, 2021filed Feb 15, 2022FY2020ended Dec 31, 2020filed Feb 16, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 14, 2019FY2017ended Dec 31, 2017filed Feb 15, 2018FY2016ended Dec 31, 2016filed Feb 16, 2017FY2015ended Dec 31, 2015filed Feb 24, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Mar 26, 2014FY2012ended Dec 31, 2012filed May 15, 2013FY2011ended Dec 31, 2011filed May 15, 2013
Operating cash flow2,9042,9532,3531,9122,2132,1261,7951,7901,346713664626681454497
Capital expenditures621655732586477453460338224216224180184126135
Free cash flow (CFO − capex)2,2832,2981,6211,3261,7361,6731,3351,4521,122497440446497328362
Depreciation and amortization487497491465448441412308242240199204209200205
Share repurchases3,2351,8581,0921,59474325062669850030020300——
Dividends paid———————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$886K
3 purchases by 3 insiders; officers and directors $886K
Sold, twelve months
$3M
2 sales by 1 insider; officers and directors $3M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 30, 2026Fuller JulieExecutive Vice Presidentoption exercise799——1,862Oct 2, 2026
Sep 30, 2026Fuller JulieExecutive Vice Presidenttax withholding274$69.83$19K1,588Oct 2, 2026
Aug 7, 2026Damelio Frank ADirectorgift6,650$0.00—14,808Aug 11, 2026
Jun 10, 2026Mccallister Michael BDirectorgift1,209$0.00—0Jun 11, 2026
May 21, 2026Stetter MarkDirectoroption exercise1,572——1,572May 26, 2026
May 20, 2026Parent Louise MDirectoroption exercise1,944——18,208May 21, 2026
May 20, 2026Parent Louise MDirectoroption exercise10,186——28,394May 21, 2026
May 13, 2026Damelio Frank ADirectoropen-market buy6,650$75.39$501K21,458May 13, 2026
May 13, 2026Bisaro PaulDirectoropen-market buy2,000$75.88$152K27,862May 13, 2026
May 11, 2026Mccallister Michael BDirectoropen-market buyindirect3,000$77.76$233K24,524May 12, 2026
Apr 30, 2026Esch KevinExecutive Vice Presidentoption exercise259——653May 1, 2026
Apr 30, 2026Esch KevinExecutive Vice Presidenttax withholding75$114.97$9K578May 1, 2026
Mar 31, 2026Sarbaugh KeithExecutive Vice Presidentoption exercise1,528——3,870Apr 1, 2026
Mar 31, 2026Sarbaugh KeithExecutive Vice Presidenttax withholding524$118.21$62K3,346Apr 1, 2026
Mar 9, 2026Norden GregoryDirectorgift1,213$0.00—0Mar 10, 2026
Feb 19, 2026Mccallister Michael BDirectorother413$127.28$53K1,209Feb 23, 2026
Feb 19, 2026Mccallister Michael BDirectoroption exercise1,619——1,622Feb 23, 2026
Feb 19, 2026Norden GregoryDirectoroption exercise1,619——1,619Feb 23, 2026
Feb 19, 2026Norden GregoryDirectorother406$127.28$52K1,213Feb 23, 2026
Feb 19, 2026Broadhurst VanessaDirectoroption exercise1,619——4,437Feb 23, 2026
Feb 19, 2026Broadhurst VanessaDirectorother517$127.28$66K3,920Feb 23, 2026
Feb 19, 2026Fuller JulieExecutive Vice Presidentoption exercise750——1,353Feb 23, 2026
Feb 19, 2026Fuller JulieExecutive Vice Presidenttax withholding290$127.28$37K1,063Feb 23, 2026
Feb 19, 2026Joseph WettenyChief Financial Officertax withholding703$127.28$89K22,113Feb 23, 2026
Feb 19, 2026Joseph WettenyChief Financial Officeroption exercise2,050——22,816Feb 23, 2026

Full insider history for ZOETIS INC., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Zoetis Inc., CIK 1555280 on EDGAR
Extract generated
October 6, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: other income FY2012
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2014
XBRL concepts behind each line

Income statement

Revenue: Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: not filed
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated October 6, 2026.

JSON file
/data/financials/ZTS.json